Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1998-05-05
1999-06-22
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
A61K 3166
Patent
active
059143231
ABSTRACT:
Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
REFERENCES:
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 4927814 (1990-05-01), Gall et al.
patent: 5019651 (1991-05-01), Kieczykowski
patent: 5270365 (1993-12-01), Gertz et al.
patent: 5462932 (1995-10-01), Brenner
Averbach, Cancer Suppl., vol. 72, No. 11, pp. 3444-3452 (1993), "New bisphosphonates in the treatment of bone metastases".
Nussbaum et al., J. of Clinical Oncology, vol. 11, No. 8, pp. 1618-1623 (1993), "Dose-response study of alendronate sodium for the treatment of cancer-associated . . .".
United States Pharmacopeia/Nat'l Formulary for 1995, "General tests and assays" water for injection, pp. 1636-1637.
United States Pharmacopeia/Nat'l Formulary for 1995, "General tests and assays" Sterility, pp. 1686-1690.
United States Pharmacopeia/Nat'l Formulary for 1995, "General tests and assays" Pyrogen, pp. 1718-1719.
United States Pharmacopeia/Nat'l Formulary for 1995, "General tests and assays" Particulates, pp. 1813-1819.
United States Pharmacopeia/Nat'I Formulary for 1995, "General tests and assays" Tonicity, p. 1813.
United States Pharmacopeia/Nat'l Formulary for 1995, "General tests and assays" pH, pp. 1819-1820.
Physician's Desk Reference, 1996, pp. 1488-1489.
Physician's Desk Reference, 1996, pp. 810-813.
Fleisch, Drugs 42(6) (1991), pp. 919-944, "Bisphosphonates--Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease".
Remington's Pharmaceutical Sciences, Chapter 84,18th ed., pp. 1549-1550.
De Marco et al., J. Pharm. & Biomed. Anal., vol. 7(12), (1989), pp. 1719-1727, "The determination of 4-amino-1-hydroxybutane-1,1-diphosphonic acid monosodium salt . . .".
Brenner Gerald S.
Ghannam Musa M.
Gerstl Robert
Merck & Co. , Inc.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Intravenous alendronate formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intravenous alendronate formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravenous alendronate formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1708236